As one of the most avid posters on this board and shareholder of the company, I would like to point out several key items that are CLEAR & FACTUAL after listening to the cc twice:
- 42% month over month growth rate from the Beyond Human Platform
- 3.1M YTD Revenue (only Q4 left to go)
- Multiple products selling well, especially Vesele and the Testosterone Booster.
- Vesele is selling 300 units PER DAY
- Will not do a reverse split just to uplist. Shareprice and timing have got to be right and then an uplist will happen as it is still a goal
- Confident that Fluticare will be approved by end of THIS year and bring in 10-15M in addition to the restated 2017 guidance of 15M...yes, that is potentially $30M folks.
- Clear that they will introduce new products as BH platform is working very well and touching millions. Sounds like even before Fluticare would launch (Q2 if approval hits by end of 2016) they would have complimentary products launched along with it to enhance this portion/segment of their product portfolio.
- Pre-paid expenses were on the high side because they want to ensure enough supply and mitigate any delays/disruptions, especially with the 3 highest-demand products. Some of this add'l supply will come months down the road and well into Q4, which is good that it got charged in Q3.
- Continue to enhance sales and partnerships outside of the US
- Margins are just simply incredible as the platform allows for more profit
- Restated at least 3 times that they are on track to finish 2016 with at least 5M - which would equate to a 1.9M Q4 but Damaj said that month over month has seen a 42% growth rate
DO THE MATH ON THAT ONE ! 2017 at 15m plus another 10-15M once Fluticare is approved.
** Folks if this is still in the 20's tomorrow and going forward - I will buy this every hour on the hour because this time next year we are looking at a $28-30M revenue company IMO. I give that a better than 75% chance with 15M in the bag. Min price target for me is 80 cents and with Fluticare approval, should easily double overnight. Keep getting the word out there about the products as it is working !!
- 42% month over month growth rate from the Beyond Human Platform
- 3.1M YTD Revenue (only Q4 left to go)
- Multiple products selling well, especially Vesele and the Testosterone Booster.
- Vesele is selling 300 units PER DAY
- Will not do a reverse split just to uplist. Shareprice and timing have got to be right and then an uplist will happen as it is still a goal
- Confident that Fluticare will be approved by end of THIS year and bring in 10-15M in addition to the restated 2017 guidance of 15M...yes, that is potentially $30M folks.
- Clear that they will introduce new products as BH platform is working very well and touching millions. Sounds like even before Fluticare would launch (Q2 if approval hits by end of 2016) they would have complimentary products launched along with it to enhance this portion/segment of their product portfolio.
- Pre-paid expenses were on the high side because they want to ensure enough supply and mitigate any delays/disruptions, especially with the 3 highest-demand products. Some of this add'l supply will come months down the road and well into Q4, which is good that it got charged in Q3.
- Continue to enhance sales and partnerships outside of the US
- Margins are just simply incredible as the platform allows for more profit
- Restated at least 3 times that they are on track to finish 2016 with at least 5M - which would equate to a 1.9M Q4 but Damaj said that month over month has seen a 42% growth rate
DO THE MATH ON THAT ONE ! 2017 at 15m plus another 10-15M once Fluticare is approved. ** Folks if this is still in the 20's tomorrow and going forward - I will buy this every hour on the hour because this time next year we are looking at a $28-30M revenue company IMO. I give that a better than 75% chance with 15M in the bag. Min price target for me is 80 cents and with Fluticare approval, should easily double overnight. Keep getting the word out there about the products as it is working !!
1
